Literature DB >> 30705857

BRMS1 expression in resected lung adenocarcinoma.

Domenico Galetta1, Pamela Pizzutilo1, Vito Longo1.   

Abstract

Entities:  

Year:  2018        PMID： 30705857      PMCID： PMC6328692          DOI： 10.21037/tlcr.2018.09.20

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  25 in total

1.  BRMS1 transcriptional repression correlates with CpG island methylation and advanced pathological stage in non-small cell lung cancer.

Authors:  Alykhan S Nagji; Yuan Liu; Edward B Stelow; George J Stukenborg; David R Jones
Journal:  J Pathol       Date:  2010-06       Impact factor: 7.996

2.  Factors associated with recurrence in patients with curatively resected stage I-II lung cancer.

Authors:  Hyeon-Kyoung Koo; Sang-Man Jin; Chang-Hoon Lee; Hyo-Jeong Lim; Jae-Joon Yim; Young Tae Kim; Seok-Chul Yang; Chul-Gyu Yoo; Sung Koo Han; Joo Hyun Kim; Young-Soo Shim; Young Whan Kim
Journal:  Lung Cancer       Date:  2010-12-18       Impact factor: 5.705

3.  Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13.

Authors:  M J Seraj; R S Samant; M F Verderame; D R Welch
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

4.  Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis.

Authors:  J Li; Y Cheng; D Tai; M Martinka; D R Welch; G Li
Journal:  Oncogene       Date:  2010-10-11       Impact factor: 9.867

5.  Prognostic significance of TAZ expression in resected non-small cell lung cancer.

Authors:  Mian Xie; Li Zhang; Chao-Sheng He; Jin-Hui Hou; Su-Xia Lin; Zhi-Huang Hu; Fei Xu; Hong-Yun Zhao
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

6.  Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma.

Authors:  Kyuichi Kadota; Jun-Ichi Nitadori; Inderpal S Sarkaria; Camelia S Sima; Xiaoyu Jia; Akihiko Yoshizawa; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  Cancer       Date:  2012-10-23       Impact factor: 6.860

7.  Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer.

Authors:  Tony Dhillon; Francesco A Mauri; Guido Bellezza; Lucio Cagini; Mattia Barbareschi; Bernard V North; Michael J Seckl
Journal:  J Thorac Oncol       Date:  2010-03       Impact factor: 15.609

8.  Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.

Authors:  Naoki Yanagawa; Charles Leduc; Derek Kohler; Mauro A Saieg; Thomas John; Jenna Sykes; Maisa Yoshimoto; Melania Pintilie; Jeremy Squire; Frances A Shepherd; Ming-Sound Tsao
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

9.  Breast cancer metastasis suppressor 1 (BRMS1) suppresses metastasis and correlates with improved patient survival in non-small cell lung cancer.

Authors:  Philip W Smith; Yuan Liu; Suzanne A Siefert; Christopher A Moskaluk; Gina R Petroni; David R Jones
Journal:  Cancer Lett       Date:  2008-12-25       Impact factor: 8.679

10.  Low BRMS1 expression promotes nasopharyngeal carcinoma metastasis in vitro and in vivo and is associated with poor patient survival.

Authors:  Rui-Xue Cui; Na Liu; Qing-Mei He; Wen-Fei Li; Bi-Jun Huang; Ying Sun; Ling-Long Tang; Mo Chen; Ning Jiang; Lei Chen; Jing-Ping Yun; Jing Zeng; Ying Guo; Hui-Yun Wang; Jun Ma
Journal:  BMC Cancer       Date:  2012-08-29       Impact factor: 4.430
View more
  1 in total

1.  Potential factors of specialists' willingness to write editorial and commentary: a retrospective study based on 5,091 invitations.

Authors:  Hengrui Liang; Lujiao Ye; Wenhua Liang; Runchen Wang; Fan Ge; Lihua Fan; Yao Zhu; Grace S Li; Stephen D Wang; Kevin Phan; Alan Sihoe; Kaiping Zhang; Jianxing He
Journal:  Ann Transl Med       Date:  2019-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.